Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea

Korean Journal of Pediatrics

Volumn 54, Issue 4, 2011, Pages 146-151

  Choi, Eun Hwa ^a   Kim, Kyung Hyo ^a   Kim, Yae Jean ^a   Kim, Jong Hyun ^a   Park, Su Eun ^a   Lee, Hoan Jong ^a   Eun, Byung Wook ^a   Jo, Dae Sun ^a   Choi, Kyong Min ^a   Hong, Young Jin ^a  

^a Seoul National University Children's Hospital   (South Korea)

Author keywords

Pneumococcal conjugate vaccine; Serotype; Streptococcus pneumoniae

Indexed keywords

EID: 79959813399     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2011.54.4.146     Document Type: Article

References (13)

1. The Korean Pediatric Society. Pneumococcal vaccine. In: Lee HJ, editor. Immunization Guideline. 6th ed. Seoul: The Korean Pediatric Society, 2008;196-216.
2. Dagan R, Jacobs MR, Greenberg D. Pneumococcal infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan S, editors. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: WB Saunders, 2004;1204-58.
3. Lee JH, Cho HK, Kim KH, Kim CH, Kim DS, Kim KN, et al. Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): A retrospective multicenter study. J Korean Med Sci 2011;26:174-83.
4. Kim SH, Song EK, Lee JH, Kim NH, Lee JA, Choi EH, et al. Changes of serotype distribution of Streptococcus pneumoniae isolated from children in Korea over a 15 year-period (1991-2005). Korean J Pediatr Infect Dis 2006;13:89-98.
5. Lee TJ, Chun JK, Choi KM, Yong DE, Lee KW, Kim DS. Trends in serotype distribution of clinical isolates of Streptococcus pneumoniae: a single center experience from 2001 to 2006. Korean J Pediatr Infect Dis 2006;13:115-23.
6. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee HJ, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81.
7. Korean Centers for Disease Control and Prevention. Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae clinical isolates in Korea. Public Health Weekly Report 2010;3:1-7.
8. World Health Organization. Technical Report Series, No. 927, Annex 2. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, 2009.
9. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al. Immunogenicity of the 10-Valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) vompared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(4 Suppl): 66S-76S.
10. Food and Drug Administration. Prevnar 13: clinical review of new product license application. Rockville, MD: Food and Drug Administration, 2010.
11. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D forprevention of acute otitis media caused by both Streptococcus pneumoniae and nontypeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8.
12. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59:258-61.
13. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children - Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR 2010;59:1-19 (No. RR-11).